Galectin Therapeutics Inc. (GALT)

Market Cap	77.82M
Revenue (ttm)	n/a
Net Income (ttm)	-45.23M
Shares Out	62.76M
EPS (ttm)	-0.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	228,079
Open	1.250
Previous Close	1.250
Day's Range	1.210 - 1.280
52-Week Range	0.730 - 4.270
Beta	0.83
Analysts	Hold
Price Target	n/a
Earnings Date	Nov 13, 2024

About GALT

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: GALT
• Website: https://galectintherapeutics.com